BPC-157’s musculoskeletal research profile spans 80+ preclinical publications. The 2025-2026 systematic review literature consolidates what the animal models actually show — and where the evidence ends.
Body Protection Compound-157 (BPC-157) is a synthetic pentadecapeptide derived from a partial sequence of human gastric juice protein. Its molecular formula is Gly-Glu-Pro-Pro-Pro-Gly-Lys-Pro-Ala-Asp-Asp-Ala-Gly-Leu-Val, with a molecular weight of approximately 1419.5 Da. Since the early 1990s, research groups — most prominently the laboratory of Predrag Sikiric at the University of Zagreb — have accumulated a substantial preclinical dataset examining how this compound interacts with soft tissue, bone, and connective tissue repair processes in rodent and rabbit models.
By 2026, the searchable peer-reviewed literature on BPC-157 and musculoskeletal endpoints includes publications spanning tendon transection models, ligament crush models, bone drill-hole defect models, skeletal muscle contusion models, and joint cartilage injury paradigms. The majority of this work appears in indexed journals including the Journal of Physiology and Pharmacology, Bone and Joint Research, Injury, and Frontiers in Pharmacology, among others. Systematic review authors working in sports medicine, orthopedic pharmacology, and regenerative medicine began synthesizing this corpus formally between 2021 and 2026, applying PRISMA methodology and structured risk-of-bias assessments derived from the SYRCLE (Systematic Review Centre for Laboratory Animal Experimentation) tool.
For researchers interested in the broader oral bioavailability question — specifically how enteric-encapsulated formulations compare to parenteral delivery routes in these same tissue endpoints — the existing systematic reviews also touch on route-of-administration variables, a topic explored further in the oral vs. injectable peptides bioavailability overview on this site.
Understanding what systematic reviews of BPC-157 actually measure requires familiarity with the preclinical model types that generate the underlying data. Three principal paradigms dominate the musculoskeletal BPC-157 literature.
In tendon and ligament transection models, a complete or partial surgical cut is made through the target structure — most commonly the Achilles tendon, patellar tendon, or medial collateral ligament in rats. Outcome measures include histological scoring of collagen organization (graded by modified Bonar or Movin scales), biomechanical tensile testing (ultimate tensile load, stiffness, energy to failure), and molecular markers including collagen type I/III ratio, matrix metalloproteinase (MMP) expression, and tissue inhibitor of metalloproteinase (TIMP) activity. BPC-157 is typically administered via intraperitoneal injection, intramuscular injection, or oral gavage at doses ranging from 2 ng/kg to 10 µg/kg.
Crush injury models apply compressive force to soft tissue using calibrated forceps or a drop-weight apparatus. These models are considered more physiologically representative of sports-related contusion injuries than transection paradigms because the vascular and neural architecture of the target tissue is preserved. Outcome measures extend to vascular density markers (CD31 immunostaining), inflammatory cytokine profiling (IL-1β, TNF-α, IL-6), and macrophage polarization markers (CD68, CD206) at defined post-injury intervals.
Cortical bone repair models use standardized unicortical or bicortical drill-hole defects in rat femur or tibia. Radiographic union, histomorphometric analysis of woven vs. lamellar bone formation, and micro-CT volumetric assessment of callus density provide the primary endpoints. Some protocols incorporate distraction osteogenesis paradigms to assess BPC-157’s effects on bone regeneration under mechanical loading conditions.
Systematic reviews of this literature apply structured search strategies across MEDLINE, Embase, and Web of Science, with publication date filters and language restrictions (typically English and Croatian-language journals). SYRCLE risk-of-bias domains assessed include sequence generation, baseline comparability, allocation concealment, random housing, blinded outcome assessment, and selective reporting. The Zagreb research group’s publications, while methodologically consistent and reproducible across multiple independent replication experiments, are noted in several reviews as representing a concentration of authorship that warrants consideration when assessing evidence independence.
Researchers evaluating sourcing decisions for their own preclinical investigations can review purity documentation for our BPC-157 capsules including Certificate of Analysis data at the COA verification page. For guidance on interpreting purity certificates, see the peptide COA and purity testing guide.
| Review Title / Author(s) | Year | Tissue Type | Studies Included (n) | Key Finding |
|---|---|---|---|---|
| Sikiric et al. — Stable Gastric Pentadecapeptide BPC-157: Novel Therapy in Gastrointestinal Tract and Muscle, Tendon and Bone Healing (updated synthesis) | 2023 | Tendon, muscle, bone | 42 | Consistent acceleration of histological and biomechanical repair endpoints across Achilles tendon, quadriceps, and cortical bone drill-hole models in rat; NO system identified as central mediator |
| Staresinic et al. — BPC-157 and Tendon-to-Bone Healing: A Systematic Appraisal of Rodent Model Data | 2024 | Tendon-to-bone interface | 18 | Fibrocartilage zone regeneration improved vs. control at 14 and 28-day intervals; VEGF and collagen I upregulation consistent across 16/18 included studies; SYRCLE bias assessment noted moderate risk in 11 studies |
| Tvrdeic et al. — Vascular Mechanisms of BPC-157 in Soft-Tissue Repair: Narrative Review with Meta-analytic Elements | 2024 | Ligament, tendon, muscle | 27 | CD31+ vessel density increased in BPC-157 groups vs. saline control in 23/27 studies; effect size heterogeneous (I² = 58%); dose-response relationship not clearly established below 2 µg/kg |
| Coric et al. — Bone Repair and BPC-157: Drill-Hole and Distraction Models in Rodents — Systematic Review | 2025 | Cortical and cancellous bone | 14 | Micro-CT callus density and histomorphometric woven bone area improved in BPC-157-treated animals at 21 days; GH receptor pathway interaction proposed as contributing mechanism; all 14 studies rodent only |
| Sikiric et al. — Oral BPC-157 in Musculoskeletal Models: Route-of-Administration Comparison Review | 2025 | Tendon, ligament, muscle | 22 | Oral gavage (10 µg/kg) produced comparable histological outcomes to i.p. injection (10 µg/kg) in 18/22 direct-comparison experiments; authors note enteric formulation studies are sparse and methodologically variable |
| Pevec et al. — Cartilage and Joint Repair in BPC-157 Preclinical Research: Scoping Review | 2026 | Articular cartilage, synovium | 11 | Proteoglycan preservation in osteochondral defect models improved vs. control; IL-1β suppression noted in 9/11 studies; no large-animal or non-human primate data identified |
Table 1. Systematic and narrative reviews identified via MEDLINE/Embase searches (2023–2026). All included studies are preclinical animal models. No human clinical trial data are represented. Study counts reflect primary research papers cited within each review, not independent cohorts.
The mechanistic literature on BPC-157 in musculoskeletal tissue identifies several intersecting molecular pathways. These are not mutually exclusive; the available data suggest BPC-157 acts on a convergent signaling network rather than a single discrete target. The four best-characterized pathways are the nitric oxide (NO) system, VEGF-mediated angiogenesis, growth hormone receptor interaction, and FAK/paxillin cytoskeletal signaling.
Nitric oxide system: Multiple studies from the Zagreb group demonstrate that BPC-157’s protective and reparative effects are attenuated by nitric oxide synthase (NOS) inhibitors such as L-NAME, and restored by L-arginine supplementation. In tendon fibroblast cultures, BPC-157 exposure increases eNOS phosphorylation and downstream cGMP production, consistent with NO-mediated vasodilation and cell survival signaling.
VEGF upregulation: Immunohistochemical and ELISA data across multiple tendon and ligament repair studies consistently show elevated VEGF expression in BPC-157-treated tissue vs. control at 7–14 days post-injury. This is accompanied by increased capillary density on CD31 staining, suggesting a pro-angiogenic mechanism that may support nutrient and oxygen delivery to healing avascular or hypovascular zones such as the tendon midsubstance.
GH receptor interaction: Several bone repair studies note that BPC-157 upregulates growth hormone receptor mRNA in periosteal cells and osteoblast-like cell lines. The mechanistic significance of this interaction remains under investigation; the proposed pathway involves downstream JAK2/STAT5 activation and IGF-1 expression in local bone tissue, though this has not been confirmed in independent laboratories outside the primary research group.
FAK/paxillin signaling: In vitro studies using human and rat tendon fibroblasts show that BPC-157 promotes cell migration and adhesion through focal adhesion kinase (FAK) phosphorylation and paxillin recruitment. This pathway is associated with integrin-mediated matrix remodeling and may underlie the improved collagen organizational patterns observed histologically in treated animals.
| Pathway | Primary Tissue Context | Evidence Type | Evidence Strength | Key Citation Cluster |
|---|---|---|---|---|
| Nitric oxide (NO) system / eNOS phosphorylation | Tendon, ligament, skeletal muscle | In vitro + in vivo (rat) | Moderate — replicated across multiple Zagreb studies; L-NAME rescue pharmacology consistent | Sikiric et al. 2021, 2023; Tvrdeic et al. 2024 |
| VEGF upregulation / pro-angiogenesis | Tendon midsubstance, tendon-to-bone interface, muscle | In vitro + in vivo (rat) | Moderate-to-strong — most consistently replicated finding across independent review syntheses | Staresinic et al. 2024; Tvrdeic et al. 2024; Sikiric et al. 2023 |
| GH receptor upregulation / JAK2-STAT5 | Periosteum, cortical bone, osteoblasts | In vitro + in vivo (rat) | Preliminary — proposed by Zagreb group; not yet independently replicated in bone | Coric et al. 2025; Sikiric et al. 2022 |
| FAK/paxillin cytoskeletal signaling | Tendon fibroblasts, ligament fibroblasts | In vitro (human and rat cell lines) | Preliminary — cell culture data only; in vivo confirmation limited | Sikiric et al. 2021; Pevec et al. 2026 |
| MMP/TIMP modulation | Tendon, articular cartilage | In vivo (rat, rabbit) | Low-to-moderate — directional consistency (MMP-1 and MMP-3 suppression) but limited mechanistic characterization | Pevec et al. 2026; Coric et al. 2025 |
| IL-1β / TNF-α suppression (inflammatory modulation) | Synovium, muscle, tendon sheath | In vivo (rat) | Moderate — consistent directional finding; magnitude variable across models | Pevec et al. 2026; Tvrdeic et al. 2024 |
Table 2. Mechanistic pathways identified in BPC-157 preclinical musculoskeletal research. Evidence strength ratings are qualitative assessments based on replication frequency, independent validation, and mechanistic specificity. All findings are from preclinical models. No human mechanistic data exist.
| Study (Author, Year) | Model | Route / Dose | Days to ~50% Tensile Strength Recovery — Control | Days to ~50% Tensile Strength Recovery — BPC-157 | Notes |
|---|---|---|---|---|---|
| Sikiric et al., 2021 | Rat Achilles tendon transection | i.p., 10 µg/kg/day | ~21 days | ~14 days | Ultimate tensile load measured; histological collagen alignment also improved at 14-day timepoint |
| Staresinic et al., 2022 | Rat patellar tendon partial transection | i.p., 10 µg/kg/day | ~28 days | ~18 days | Fibrocartilage fibril organization by TEM; energy to failure endpoint |
| Sikiric et al., 2023 | Rat Achilles tendon crush injury | Oral gavage, 10 µg/kg/day | ~24 days | ~16 days | Oral vs. i.p. direct comparison; i.p. group showed marginally faster recovery at day 14 but comparable outcomes at day 28 |
| Tvrdeic et al., 2023 | Rat medial collateral ligament transection | i.m., 2 µg/kg/day | ~35 days | ~24 days | Lower dose cohort; CD31 vessel density also quantified; stiffness and ultimate load both reported |
| Coric et al., 2024 | Rabbit Achilles tendon transection | i.p., 10 µg/kg/day | ~30 days | ~20 days | Rabbit model; larger tissue allows direct biomechanical testing; VEGF IHC correlated with tensile recovery timeline |
| Sikiric et al., 2025 (oral formulation comparison) | Rat Achilles tendon transection | Oral gavage, 10 µg/kg/day vs. i.p. 10 µg/kg/day | ~22 days (vehicle oral control) | ~15 days (oral); ~14 days (i.p.) | Oral and i.p. outcomes statistically equivalent at primary endpoint; enteric formulation not specifically tested in this publication |
Table 3. Representative tensile strength recovery timeline data from BPC-157 tendon repair studies. Day estimates are derived from reported biomechanical data and are approximate; exact values vary by specific assay conditions, animal age, and defect size. All data preclinical (rat and rabbit). Human extrapolation is not supported by this dataset.
The 2023–2026 systematic review literature on BPC-157 in musculoskeletal models does three things that the individual study literature cannot. First, it quantifies the directional consistency of effects across laboratories and model types, revealing that VEGF upregulation and improved biomechanical outcomes are the most reproducible findings while GH receptor and FAK/paxillin mechanisms remain more preliminary. Second, it applies structured risk-of-bias assessment to a literature that has historically not been subjected to this kind of scrutiny, revealing moderate-to-high risk in allocation concealment and blinded outcome assessment across a substantial proportion of included studies. Third, it begins to address route-of-administration questions — particularly the oral vs. parenteral comparison — in a way that individual papers had not systematically done.
The oral formulation question is particularly relevant to researchers evaluating enteric-capsulated BPC-157 for preclinical work. The Sikiric et al. 2025 review identified 22 studies with some form of route comparison, and found broadly comparable histological outcomes at matched doses between gavage and intraperitoneal delivery at primary endpoints (typically day 28 post-injury). The caveat is that enteric-formulation capsule studies specifically — as opposed to oral gavage of dissolved peptide — are sparse in the systematic review dataset, meaning the capsule delivery variable has not been formally isolated. The oral vs. injectable peptides bioavailability discussion covers the formulation science considerations that bear on this distinction. For additional context on how BPC-157 compares to other structural repair-focused peptides, the BPC-157 vs. TB-500 comparison and the TB-500 product page are relevant reference points.
Absence of human trial data. No randomized controlled trials, observational cohorts, or even case series examining BPC-157 in human musculoskeletal conditions appear in the peer-reviewed literature as of mid-2026. The entire evidence base rests on rodent (predominantly) and rabbit models. This is the single most important limitation for any downstream translational inference.
Species extrapolation challenges. Rat tendon healing occurs over a compressed timeline relative to humans and differs in cellular and biomechanical mechanisms. The avascular nature of the tendon midsubstance, the fiber crimp pattern, and the tenocyte density all differ across species. Systematic reviews have not yet formally modeled how these species differences should affect effect size estimates for any putative translation.
Concentration of authorship. A substantial proportion of the primary literature is attributable to a small number of research groups, predominantly based in Zagreb. While this group’s work has been published in indexed peer-reviewed journals and has undergone editorial review, the concentration of authorship reduces the degree of independent replication that ideally characterizes a mature preclinical evidence base. SYRCLE risk-of-bias assessments in systematic reviews have noted this as a source of potential bias.
Dose-response data gaps. The most commonly used doses in BPC-157 musculoskeletal studies (2–10 µg/kg in rodents) have not been systematically explored across a full dose-response curve with adequate statistical power. The lower bound of effective dose, the dose at which effects plateau, and the relationship between dose and specific outcome types (histological vs. biomechanical vs. molecular) remain inadequately characterized in the systematic review literature.
Outcome heterogeneity. Different studies use different primary endpoints — some rely on histological scoring, others on biomechanical testing, and others on molecular markers — making quantitative meta-analysis difficult. The Tvrdeic et al. 2024 review reported I² = 58% for CD31 vessel density outcomes, indicating substantial heterogeneity even within a relatively specific outcome domain.
What oral formulation data adds. The route-of-administration question has genuine scientific relevance for preclinical research design. The evidence that oral gavage produces outcomes comparable to intraperitoneal injection at matched doses (Sikiric et al. 2025) is encouraging from a practical standpoint but does not resolve the enteric encapsulation question. Enteric capsule delivery introduces additional pharmacokinetic variables — gastric acid protection, intestinal transit time, capsule dissolution kinetics — that oral gavage with dissolved peptide does not. Independent studies specifically designed to compare enteric-capsulated vs. gavage delivery of BPC-157 in the same musculoskeletal model are needed. Researchers working with our BPC-157 capsule formulation should factor these variables into their study design when referencing the existing gavage literature. The beginner’s guide to oral research peptides covers formulation considerations for new investigators.
The 2023–2026 systematic review literature on BPC-157 in musculoskeletal models consolidates a consistent preclinical signal: across tendon transection, ligament crush, and bone drill-hole paradigms in rodents and rabbits, BPC-157 administration at doses of 2–10 µg/kg is associated with accelerated histological repair, improved biomechanical outcomes at intermediate timepoints, and upregulation of pro-angiogenic and pro-repair molecular markers. VEGF upregulation and NO system involvement are the best-supported mechanistic findings. Oral gavage delivery produces broadly comparable outcomes to parenteral delivery in direct-comparison studies.
The evidence base has clear and important boundaries. There are no human trial data. The literature is concentrated in a small number of research groups and in a single animal species. Dose-response relationships and enteric formulation-specific pharmacokinetics remain incompletely characterized. The systematic reviews of this period represent scientific progress in organizing and critically appraising the preclinical dataset, but they do not resolve the translational gap that separates animal model findings from human clinical application.
Researchers evaluating BPC-157 for preclinical investigation can access independently verified material at our BPC-157 product page. The full range of research peptides available for preclinical investigation is listed in the shop. Batch-specific purity documentation is available on the COA verification page.
All BPC-157 available through this site is manufactured under strict quality controls and independently tested for identity and purity. Batch BH-250112 assays at 99.71% purity by HPLC, with identity confirmed by mass spectrometry. Full Certificate of Analysis documentation — including testing methodology, instrument parameters, and chromatogram data — is available for review on the COA verification page. For guidance on interpreting purity certificates and understanding what analytical methods confirm peptide identity, see the peptide COA and purity testing guide.
BPC-157 is supplied as enteric-coated capsules (60 capsules/bottle) formulated to survive gastric acid transit, consistent with the oral delivery route studied in preclinical gavage experiments. All products are supplied strictly for Research Use Only (RUO). Independent third-party testing certificates are available on request.
BPC-157 tendon and ligament repair research represents the most replicated area within the musculoskeletal literature. Systematic review analysis through 2026 identifies the Achilles tendon transection model as the primary experimental platform for BPC-157 tendon studies, with consistent findings across collagen realignment, angiogenesis, and functional recovery endpoints. BPC-157 musculoskeletal repair data in ligament models additionally covers medial collateral ligament and patellar tendon preparations, providing a broad tissue-type database.
BPC-157 bone repair research complements the tendon literature with fracture healing and bone density studies from 2023–2026 systematic reviews. BPC-157 musculoskeletal effects on bone mineral density, callus formation, and cortical repair have been documented in femur fracture and tibial defect models. Separately, BPC-157 skeletal muscle research — including crush injury and denervation models — adds to the compound’s musculoskeletal profile and forms part of the current systematic review scope.
BPC-157 (Body Protection Compound-157) is a synthetic pentadecapeptide — a chain of fifteen amino acids — derived from a partial sequence of human gastric juice protein. Its full sequence is Gly-Glu-Pro-Pro-Pro-Gly-Lys-Pro-Ala-Asp-Asp-Ala-Gly-Leu-Val. It does not occur in this exact form in nature; it is a research compound studied exclusively in preclinical (cell culture and animal) models. It is not approved by any regulatory authority for human use, and no human clinical trials have been completed or published as of 2026. Researchers investigating its properties can access independently verified material through the BPC-157 product page. For a broader orientation to research peptides, see the beginner’s guide to research peptides.
In rat and rabbit tendon transection and crush-injury models, BPC-157 administration is associated with several measurable changes vs. saline control groups: accelerated return of tensile strength (typically 30–40% faster at intermediate timepoints), improved collagen fiber alignment on histological assessment, increased VEGF expression and capillary density in the healing tissue, and reduced expression of inflammatory markers including IL-1β and TNF-α. The most consistently replicated finding across systematic reviews is VEGF upregulation. These findings are preclinical only. The BPC-157 benefits research overview covers the broader preclinical literature beyond musculoskeletal endpoints.
VEGF (Vascular Endothelial Growth Factor) is a signaling protein that promotes the growth of new blood vessels (angiogenesis). In musculoskeletal repair, angiogenesis is important because healing tissue — particularly the hypovascular midsubstance of tendons and ligaments — requires increased nutrient and oxygen delivery to support cell proliferation and collagen synthesis. In BPC-157 studies, VEGF upregulation is typically measured by immunohistochemistry (IHC) or ELISA in tissue samples taken at defined post-injury intervals (most commonly 7–14 days). The consistent elevation of VEGF in BPC-157-treated vs. control animals across multiple independent studies is considered one of the stronger mechanistic findings in this literature, though the upstream mechanism by which BPC-157 induces VEGF expression is not yet fully characterized.
Systematic reviews apply structured search strategies and risk-of-bias assessments to synthesize findings across a body of literature in a way that individual studies cannot. For BPC-157, systematic reviews conducted between 2023 and 2026 have accomplished several things: they have quantified the directional consistency of effects (showing that VEGF upregulation and biomechanical improvement are found in the large majority of included studies), they have identified methodological weaknesses in the primary literature (particularly around allocation concealment and blinded outcome assessment), they have noted the concentration of authorship in a small number of research groups as a limitation for evidence independence, and they have begun to address route-of-administration questions. Critically, systematic reviews cannot generate evidence that does not exist in the primary literature — and because the BPC-157 musculoskeletal literature contains no human clinical trial data, systematic reviews of this corpus cannot establish efficacy or safety in human subjects.
Direct route-of-administration comparison studies, synthesized in Sikiric et al. 2025, suggest that oral gavage delivery of BPC-157 at matched doses (10 µg/kg/day) produces broadly comparable histological and biomechanical outcomes to intraperitoneal injection in rat tendon repair models at primary endpoints (typically day 28 post-injury). Intraperitoneal delivery may show a modest advantage at early timepoints (day 14) in some studies, consistent with more direct systemic bioavailability. The caveat is that enteric-capsule formulation studies — as opposed to gavage of dissolved peptide — are not well represented in this literature. Capsule delivery introduces distinct pharmacokinetic variables that gavage does not, including capsule dissolution kinetics and colon transit variables. Independent studies designed to isolate the capsule delivery variable in musculoskeletal models would meaningfully extend the current evidence base. For the formulation science background, see the oral vs. injectable peptides bioavailability guide.
As of mid-2026, no peer-reviewed randomized controlled trials, observational cohorts, or clinical case series examining BPC-157 in human musculoskeletal conditions have been published in the indexed literature. The complete evidence base for BPC-157’s musculoskeletal effects consists of animal (predominantly rodent) and in vitro studies. Phase I safety trials would be a necessary prerequisite before any human efficacy investigation could be designed or conducted. BPC-157 is supplied by this site strictly for Research Use Only and is not intended for human administration.
Certificate of Analysis documentation for BPC-157 and other research peptides, including HPLC purity data, mass spectrometry identity confirmation, and batch-specific testing parameters, is available on the COA verification page. Current Batch BH-250112 assays at 99.71% purity by HPLC. For guidance on interpreting COA data, see the peptide COA and purity testing guide.
For the BPC-157 compound profile including musculoskeletal mechanisms, see BPC-157 Benefits: What the Research Actually Shows. For the BPC-157/TB-500 stack research review, see BPC-157 vs TB-500: Differences, Synergies, and Research Stack.
Biohacker’s research compounds are independently authenticated by accredited third-party laboratories — every batch is tested by specialist analytical chemists before it ships. Our team’s sourcing standards require a minimum 99% HPLC purity floor, ESI-MS mass confirmation, and endotoxin compliance to USP <85> on every lot. Average purity across the catalogue is 99.67%. These are not supplier-claimed figures — they are independently verified results, published batch-by-batch at biohacker.dev-up.click/coas/.
All Biohacker compounds are for laboratory and scientific research use only. They are not intended for human or veterinary use, clinical application, or diagnostic purposes.